Agilon Health (AGL) reported $1.39 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 5.9%. EPS of -$0.25 for the same period compares to -$0.07 a year ago.
The reported revenue represents a surprise of -4.98% over the Zacks Consensus Estimate of $1.47 billion. With the consensus EPS estimate being -$0.11, the EPS surprise was -127.27%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Agilon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Avg. Medicare Advantage Members: 498,000 compared to the 493,100 average estimate based on two analysts.
- Revenues- Other operating: $2.94 million versus $3.16 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -7.4% change.
- Revenues- Medical services: $1.39 billion compared to the $1.46 billion average estimate based on five analysts. The reported number represents a change of -5.9% year over year.
View all Key Company Metrics for Agilon here>>>
Shares of Agilon have returned -30% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agilon Health, Inc. (AGL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
